Work

Genotype-specific Response to 144-week Entecavir Therapy for HBeAg-positive Chronic Hepatitis B with a Particular Focus on Histological Improvement: A Prospective Study

Year: 2025

Type: article

Abstract: Background and Aims: Chronic hepatitis B (CHB) poses a major global health burden, with China particularly affected. Effective antiviral therapy is crucial to prevent disease progression, but responses may vary by Hepatitis B virus (HBV) genotype. This prospective study aimed to compare genotype-specific responses to 144-week entecavir (ETV) therapy in HBeAg-positive CHB patients, with particular emphasis on histological improvement assessed through paired liver biopsies. Methods: , serum HBV DNA < 100 IU/mL), HBeAg seroconversion, and ALT normalization. Results: = 0.140). All patients achieved ALT normalization by week 48, with no safety concerns. Conclusions: HBV genotype B demonstrates superior histological responses to ETV therapy compared with genotype C, supporting the clinical value of HBV genotyping for personalized CHB management. These findings highlight the importance of considering viral genotype when evaluating treatment outcomes.

Source: Journal of Clinical and Translational Hepatology

DOI: 10.14218/jcth.2025.00533

Authors: Lexin Liu, Qiumiao Xu, Shanshan Lin, Zehui Wei, Guoxin Huang

Institutions: Guangzhou University of Chinese Medicine, Guangdong Provincial Hospital of Chinese Medicine

Language: English

Topic: Hepatitis B Virus Studies

Subfield: Epidemiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: diamond

OpenAlex ID: W7117756063

FWCI:

Cites:

Cited by:

Related to: